Vor Biopharma Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Vor Biopharma Inc. is holding its 2024 Annual Meeting of Stockholders virtually on May 23, 2024, to elect directors, approve an equity plan amendment, and ratify auditor selection.</b>

AI Summary

Vor Biopharma Inc. (VOR) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. Annual Meeting scheduled for May 23, 2024, held virtually. Election of two Class III director nominees for three-year terms. Vote on amending the 2021 Equity Incentive Plan to increase share reserve. Ratification of Ernst & Young LLP as independent auditor for FY 2024. Notice provided electronically to stockholders, with paper copies available upon request.

Why It Matters

For investors and stakeholders tracking Vor Biopharma Inc., this filing contains several important signals. The virtual format may impact shareholder engagement and accessibility compared to in-person meetings. The proposed amendment to the equity incentive plan could dilute existing shareholders if not managed carefully.

Risk Assessment

Risk Level: low — Vor Biopharma Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.

Analyst Insight

Stockholders should review the director nominees and the proposed equity plan amendment before the May 23rd meeting.

Key Numbers

• 2027 — Director Term Expiration (Director terms will expire at the 2027 Annual Meeting.)
• 2034 — Equity Plan Amendment End Year (The equity plan amendment is effective through calendar year 2034.)
• 4% — Current Share Reserve Addition (Current share reserve addition to the equity plan.)
• 5% — Proposed Share Reserve Addition (Proposed share reserve addition to the equity plan.)

Key Players & Entities

• Vor Biopharma Inc. (company) — Registrant and filer of the proxy statement.
• May 23, 2024 (date) — Date of the Annual Meeting of Stockholders.
• Ernst & Young LLP (company) — Proposed independent registered public accounting firm.
• 2021 Equity Incentive Plan (plan) — Plan to be amended and restated.

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with SEC rules regarding proxy solicitations and annual meetings.
• Equity Incentive Plan Dilution [medium — financial]: Increasing the share reserve in the equity plan could lead to shareholder dilution.

Industry Context

Vor Biopharma operates in the biotechnology sector, focusing on developing therapies. Annual meetings are standard for public companies to address corporate governance and shareholder matters.

Regulatory Implications

The filing adheres to regulations set by the Securities and Exchange Commission (SEC) for proxy statements, ensuring transparency in corporate governance.

What Investors Should Do

1. Review the qualifications of the director nominees.
2. Understand the implications of the proposed amendment to the 2021 Equity Incentive Plan.
3. Confirm voting instructions and deadlines for the May 23, 2024 meeting.

Key Dates

• 2024-05-23: Annual Meeting of Stockholders — Key date for voting on proposals and electing directors.

Glossary

DEF 14A

Definitive Proxy Statement filed with the SEC. (Standard filing for annual meetings, providing details on proposals and voting.)

Class III Director Nominees

Directors nominated for a specific class with a three-year term. (Shareholders vote on the election of these directors.)

Equity Incentive Plan

A plan that provides employees and directors with equity-based compensation. (The proposed amendment affects the number of shares available for future grants.)

Year-Over-Year Comparison

This is a DEF 14A filing for the 2024 Annual Meeting, following the typical structure for such corporate events.

Key Financial Figures

• $0.0001 — f record of shares of our common stock, $0.0001 par value per share (Common Stock), or

Filing Documents

• d798120ddef14a.htm (DEF 14A) — 581KB
• g798120g17d21.jpg (GRAPHIC) — 27KB
• g798120g89a99.jpg (GRAPHIC) — 38KB
• g798120g94g94.jpg (GRAPHIC) — 154KB
• g798120g95g95.jpg (GRAPHIC) — 177KB
• 0001193125-24-090781.txt (&nbsp;) — 1120KB

Security Ownership of Certain Beneficial Owners and

Security Ownership of Certain Beneficial Owners and Management 34

Executive Compensation

Executive Compensation 37 Director Compensation 44 Equity Compensation Plans at December 31, 2023 45 Certain Relationships and Related Party Transactions 46 Householding of Proxy Materials 48 Other Matters 49 Appendix 1: Amended and Restated 2021 Equity Incentive Plan 1 i Table of Contents VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, Massachusetts 02140 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 23, 2024 This proxy statement (the Proxy Statement) contains information about our 2024 Annual Meeting of Stockholders of Vor Biopharma Inc. (the Annual Meeting). The Annual Meeting will be held on Thursday, May 23, 2024, beginning at 12:00 p.m. Eastern Time. The Annual Meeting will be a virtual meeting held via the internet at a virtual web conference at www.virtualshareholdermeeting.com/VOR2024. There will not be a physical meeting location, and stockholders will not be able to attend the Annual Meeting in person. The logistics of the virtual meeting are discussed more fully in this Proxy Except where the context otherwise requires, references to Vor Bio, Vor, we, us, our and similar terms refer to Vor Biopharma Inc. and its consolidated subsidiary. References to our website are inactive textual references only and the contents of our website are not incorporated by reference into this Proxy This Proxy Statement and the enclosed proxy card are being furnished in connection with the solicitation of proxies by our board of directors (the Board) for use at the Annual Meeting and at any adjournment of that meeting. All proxies will be voted in accordance with the instructions they contain. If you do not specify your voting instructions on your proxy, it will be v

View Full Filing

View this DEF 14A filing on SEC EDGAR